The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry
Open accessAbstract
Background: We evaluated the overall and site‐specific incidence of cancer in subjects with primary immunodeficiency diseases (PIDD) enrolled in the United States Immune Deficiency Network (USIDNET) registry compared with age‐adjusted cancer incidence in the Surveillance, Epidemiology and End Results Program (SEER) database. Objective: We hypothesized that subjects with PIDD would have an increased incidence of cancer due to impaired immune function. Methods: Overall and site‐specific cancer incidence rates were evaluated in subjects with PIDD (n = 3658) enrolled in the USIDNET registry from 2003 to 2015 and compared with age‐adjusted incidence rates in the SEER database. Results: We observed a 1.42‐fold excess relative risk of cancer in subjects with PIDD compared with the age‐adjusted SEER population (P < .001). Men with PIDD had a 1.91‐fold excess relative risk of cancer compared with the age‐adjusted male population (P < .001), while women with PIDD had similar overall cancer rates compared with the age‐adjusted female population. Of the 4 most common malignancies in men and women in SEER (lung, colon, breast, and prostate cancers), we found no significant increase in these diagnoses in subjects with PIDD. Significant increases in lymphoma in both men (10‐fold increase, P < .001) and women (8.34‐fold increase, P < .001) with PIDD were observed. Conclusions: Excess incidence of cancer occurred in subjects with PIDD. An excess of lymphoma in specific PIDD populations principally drove this increased incidence, while no increased risk of the most common solid tumor malignancies was observed. These data point to a restricted role of the immune system in protecting from specific cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Spectrum of cancer risk among US solid organ transplant recipients
Engels, E. A., Pfeiffer, R. M., Fraumeni, J. F., Kasiske, B. L., Israni, A. K., Snyder, J. J., Wolfe, R. A., Goodrich, N. P., Bayakly, A. R., Clarke, C. A., et al. (2011) · JAMA · doi:10.1001/jama.2011.1592 · Cited by 1,524
Cited by
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Barmettler, S., Ong, M.-S., Farmer, J. R., Choi, H., & Walter, J. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.4169 · Cited by 357
Early-onset autoimmunity associated with SOCS1 haploinsufficiency
Hadjadj, J., Castro, C. N., Tusseau, M., Stolzenberg, M.-C., Mazerolles, F., Aladjidi, N., Armstrong, M., Ashrafian, H., Cutcutache, I., Ebetsberger-Dachs, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18925-4 · Cited by 156
Tucci, F., Galimberti, S., Naldini, L., Valsecchi, M. G., & Aiuti, A. (2022) · Nature Communications · doi:10.1038/s41467-022-28762-2 · Cited by 145
Pillay, B. A., Avery, D. T., Smart, J. M., Cole, T., Choo, S., Chan, D., Gray, P. E., Frith, K., Mitchell, R., Phan, T. G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127527 · Cited by 43
Metadata
- Authors
- Mayor, P. C., Eng, K. H., Singel, K. L., Abrams, S. I., Odunsi, K., Moysich, K. B., Fuleihan, R., Garabedian, E., Lugar, P., Ochs, H. D., Bonilla, F. A., Buckley, R. H., Sullivan, K. E., Ballas, Z. K., Cunningham-Rundles, C., & Segal, B. H.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 141
- Issue
- 3
- Pages
- 1028-1035
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2621980896
- Cited by
- 247
- References
- 2
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.